Navigation Links
Neuro Kinetics Presenting New Balance & Dizziness Research at American Balance Society Conference

PITTSBURGH, March 3, 2011 /PRNewswire/ -- Neuro Kinetics, Inc. (NKI) (, manufacturers of noninvasive medical diagnostic equipment used worldwide to test for vestibular and neurological conditions, said today that it co-presented two research studies at this week's American Balance Society conference meeting in Scottsdale, Arizona.

The research continues the company's push to expand and refine the clinical testing that can be conducted with its medical equipment in the diagnosis of balance and dizziness conditions. Studies suggest that 50 percent of all individuals suffer from balance and equilibrium conditions during their lifetimes. The elderly are particularly vulnerable as falls can lead to devastating life-threatening consequences.

The first paper for the American Balance Society conference detailed the collection of normative patient data using video oculography (VOG) based eye tracking with a rotational (Barany) chair. The paper -- co-authored by Dr. Alexander Kiderman, NKI's chief technology officer, and Dr. Jorge Gonzalez, a professor in the Department of Audiology and Speech Pathology at Bloomsburg University – reported on the data collection work at Bloomsburg.

Data was collected for four types of rotational tests: Sinusoidal Harmonic Acceleration (SHA), Step Testing, Visual Enhancement (VVOR) and Visual Suppression (VF).

(Read abstract here.)  - link to

The second paper focused on comparing static and dynamic tests of Subjective Visual Vertical (SVV) which measure the deviation between a patient's vertical perception and actual gravitational perception.  The study addresses a question in the testing for balance and dizziness disorders about whether or not to consider the static SVV results during the dynamic SVV test.

The paper was co-authored by Dr. Kiderman; along with Dr. Howard Mango and Dr. Cara Makuta, both of the Newport Mesa Audiology Balance & Ear Institute in Newport, California, where the research was conducted.

(Read abstract here.) - link to

"We're delighted to be able to offer important new research to the community of balance specialists from around the world," said J. Howison Schroeder, NKI president and CEO. "Great strides are being made in the understanding of balance and equilibrium disorders and we're proud to be a leader in expanding the knowledge base."


Neuro Kinetics, Inc. (NKI) is the world leader in eye-tracking technology and non-invasive neuro-otologic diagnostic testing.Central to its product mix and technological advances is the premise that the eye is the portal to the brain.  Research has shown the detection of abnormal eye reflexes can indicate the presence of more than 200 diseases and medical conditions. 

For more than 25 years, NKI has supplied comprehensive neuro-otologic diagnostic tools to audiologists, ENT's, neuro-otologists, neuro-ophthalmologists and neurologists around the globe. The company's patented products include the I-Portal® NOTC (Neuro-Otologic Test Center), I-Portal® VNG (Video Nystagmography) and I-Portal® VOG (Video Oculography), along with related accessories, software, training and support services. MEDIA CONTACTJohn BuckmanBuckman Communications, for Neuro Kinetics, Inc.+ 1 412-381-2900 or

SOURCE Neuro Kinetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
5. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
6. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
9. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
10. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
11. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
Post Your Comments:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):